Iscalimab

DB15260Investigational

Iscalimab is under investigation in clinical trial NCT03905525 (Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome).

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 5
Curator reviewed
Code names: CFZ533

Resolves to

Compound

UNII0628T707D0CAS2031153-61-2

Targets

P25942CD40

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Iscalimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account